EA199900725A1 - Синергетические комбинации сульфонилмочевины и глитазона при лечении диабета - Google Patents

Синергетические комбинации сульфонилмочевины и глитазона при лечении диабета

Info

Publication number
EA199900725A1
EA199900725A1 EA199900725A EA199900725A EA199900725A1 EA 199900725 A1 EA199900725 A1 EA 199900725A1 EA 199900725 A EA199900725 A EA 199900725A EA 199900725 A EA199900725 A EA 199900725A EA 199900725 A1 EA199900725 A1 EA 199900725A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glitazone
diabetes
sulfonilm
urine
treatment
Prior art date
Application number
EA199900725A
Other languages
English (en)
Inventor
Рендал В. Виткомб
Original Assignee
Варнер Ламберт Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Варнер Ламберт Компани filed Critical Варнер Ламберт Компани
Publication of EA199900725A1 publication Critical patent/EA199900725A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Комбинации антидиабетического средства сульфонилмочевины и антидиабетического средства глитазона являются полезными для лечения сахарного диабета и улучшения гликемического контроля.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900725A 1997-02-19 1997-12-01 Синергетические комбинации сульфонилмочевины и глитазона при лечении диабета EA199900725A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (1)

Publication Number Publication Date
EA199900725A1 true EA199900725A1 (ru) 2000-04-24

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900725A EA199900725A1 (ru) 1997-02-19 1997-12-01 Синергетические комбинации сульфонилмочевины и глитазона при лечении диабета

Country Status (29)

Country Link
US (2) US5859037A (ru)
EP (1) EP0957923A1 (ru)
JP (1) JP2001512478A (ru)
KR (1) KR20000071179A (ru)
CN (1) CN1244801A (ru)
AR (1) AR011829A1 (ru)
AU (1) AU741215B2 (ru)
BG (1) BG103671A (ru)
BR (1) BR9714505A (ru)
CA (1) CA2272478A1 (ru)
CZ (1) CZ289299A3 (ru)
EA (1) EA199900725A1 (ru)
EE (1) EE9900345A (ru)
GT (1) GT199800037A (ru)
HN (1) HN1997000167A (ru)
HU (1) HUP0001528A3 (ru)
IL (1) IL130027A (ru)
IS (1) IS5058A (ru)
NO (1) NO993982L (ru)
NZ (1) NZ336002A (ru)
PA (1) PA8447401A1 (ru)
PE (1) PE74399A1 (ru)
PL (1) PL335166A1 (ru)
SK (1) SK111899A3 (ru)
SV (1) SV1998000010A (ru)
TR (1) TR199902033T2 (ru)
UY (1) UY24893A1 (ru)
WO (1) WO1998036755A1 (ru)
ZA (1) ZA981343B (ru)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
AP1600A (en) * 1997-06-18 2006-04-28 Smithkline Beecham Plc Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
PL195136B1 (pl) * 1997-06-18 2007-08-31 Smithkline Beecham Plc Kombinacja zawierająca 5-[4-[2-(N-metylo-N-(2-pirydylo)amino)etoksy]-benzylo] tiazolidyno-2,4-dion i jej zastosowanie
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) * 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
CN101164618A (zh) * 1998-12-24 2008-04-23 症变治疗公司 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
CA2367955C (en) * 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
ATE266409T1 (de) * 2000-04-13 2004-05-15 Pfizer Prod Inc Synergistische wirkung von glyburide und milrinone
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004026241A2 (en) 2002-09-20 2004-04-01 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
WO2006126673A1 (ja) * 2005-05-27 2006-11-30 Daiichi Sankyo Company, Limited 組み合わせによる糖尿病治療薬
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
CA2622069A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
BRPI0620020A2 (pt) 2005-12-22 2011-10-25 Takeda Pharmaceutical preparação sólida, e, partìcula revestida
WO2008026668A1 (fr) * 2006-08-31 2008-03-06 Daiichi Sankyo Company, Limited Composition médicale contenant un agent d'amélioration de la résistance à l'insuline
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
ES2638977T3 (es) 2007-12-04 2017-10-24 Biogen Chesapeake Llc Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
CA3213470A1 (en) 2008-12-04 2010-06-10 Chongxi Yu High penetration compositions and their applications
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
BR112012011237A2 (pt) * 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
CA2806619C (en) 2010-05-24 2018-05-22 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
EP4039208B1 (en) 2011-01-19 2023-08-30 Fractyl Health, Inc. Devices for the treatment of tissue
CN104244958B (zh) 2011-11-23 2017-11-17 澳星医疗私人有限公司 改进的协同抗糖尿病组合物
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
IL296643A (en) 2012-02-27 2022-11-01 Fractyl Health Inc Heat excision systems, devices and methods for tissue treatment
WO2013159066A1 (en) 2012-04-19 2013-10-24 Fractyl Laboratories, Inc. Tissue expansion devices, system and methods
WO2014022436A1 (en) 2012-07-30 2014-02-06 Fractyl Laboratories Inc. Electrical energy ablation systems, devices and methods for the treatment of tissue
EP2882362B1 (en) 2012-08-09 2024-01-03 Fractyl Health, Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
US11986235B2 (en) 2013-09-12 2024-05-21 Fractyl Health, Inc. Systems, methods and devices for treatment of target tissue
KR102284469B1 (ko) 2013-11-22 2021-08-02 프랙틸 헬쓰, 인코포레이티드 위장관에 치료 제한부를 생성하기 위한 시스템, 장치 및 방법
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
WO2016011269A1 (en) * 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
US9757535B2 (en) 2014-07-16 2017-09-12 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
CA2965502A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2021102423A1 (en) * 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
TR199902033T2 (xx) 2000-02-21
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
SK111899A3 (en) 2000-09-12
EE9900345A (et) 2000-02-15
IL130027A (en) 2005-09-25
IS5058A (is) 1999-05-27
PA8447401A1 (es) 2001-12-14
NO993982D0 (no) 1999-08-18
NZ336002A (en) 2002-03-28
ZA981343B (en) 1998-11-16
WO1998036755A1 (en) 1998-08-27
US5972973A (en) 1999-10-26
BG103671A (en) 2000-04-28
SV1998000010A (es) 1999-02-02
CA2272478A1 (en) 1998-08-27
AR011829A1 (es) 2000-09-13
AU741215B2 (en) 2001-11-29
HUP0001528A3 (en) 2000-12-28
KR20000071179A (ko) 2000-11-25
NO993982L (no) 1999-08-18
CN1244801A (zh) 2000-02-16
PL335166A1 (en) 2000-04-10
UY24893A1 (es) 1998-07-10
US5859037A (en) 1999-01-12
JP2001512478A (ja) 2001-08-21
EP0957923A1 (en) 1999-11-24
AU5590898A (en) 1998-09-09
HN1997000167A (es) 1999-02-09
BR9714505A (pt) 2000-03-21
PE74399A1 (es) 1999-08-20
CZ289299A3 (cs) 1999-11-17
IL130027A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
EA199900725A1 (ru) Синергетические комбинации сульфонилмочевины и глитазона при лечении диабета
AR020973A1 (es) Combinacion para diabetes
ATE319823T1 (de) Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
ATE246197T1 (de) Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
DE69633949D1 (de) Methode zur Konservierung von Leukozyten mittels CLA
DE3670022D1 (de) Vorrichtung zum schneiden von biologischen geweben mit plasmaboegen.
EA199800667A1 (ru) Новые фенантридины
DE59910083D1 (de) Verwendung von Thiazolidin- oder Pyrrolidinderivaten von Aminosäuren als antihyperglykämische Mittel
DE69019412T2 (de) Absorptionsmikroskopie und/oder -spektroskopie mit Abtastmikroskopiesteuerung.
ATE364704T1 (de) Mutanten von op-1
DE69004242D1 (de) Laktoferrinhydrolysat zur Verwendung als antibakterielles Mittel.
DE58909029D1 (de) Bauelement zur Absorption von Energie.
ATE295423T1 (de) Phosphodiesterase 8
DK1017408T3 (da) Anvendelse af tetrahydrolipstatin i behandling af diabetes type II
MX26415A (es) Piridin-m-oxidos sustituidos en posiciones 2,4 y 2,5, procedimiento para su preparacion asi como su empleo
IT1240486B (it) Procedimento di ammollo enzimatico per pelli e pellami.
DE69006149D1 (de) Kohlenstoffelektrode.
EA199800816A1 (ru) Способы лечения и профилактики интерстициального цистита
EA200000140A1 (ru) Способ лечения диабета тиазолидиндионом, средством, усиливающим секрецию инсулина, и ингибитором альфа-глюкозидазы
DE69003211D1 (de) Fahrzeug mit neigbaren Kettenantrieben.
DE69006978T2 (de) MOSFET-Verarmungsanordnung.
DE69823739D1 (de) Glycin zur Vorbeugung oder Behandlung von Transplantatabstossungen
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
FI910896A0 (fi) 6-substituerade hexahydrobens (cd) indoler.
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff